Learn More About Qualifying for Clinical Trials
Dr. Anup Kasi provides in-depth information and answers questions about qualifying for pancreatic cancer clinical trials.
Testing a Combination for Metastatic Pancreatic Cancer
A clinical trial tests an investigational drug, immunotherapy, and radiation in combination against advanced pancreatic cancer.
A New Vaccine for Advanced Pancreatic Cancer
An mRNA vaccine that works against KRAS mutations is being tested with and without immunotherapy for advanced or metastatic pancreatic cancer.
Safety and Effectiveness of a New Drug for Advanced Pancreatic Cancer
Researchers are testing dose safety and effectiveness of a new drug for pancreatic cancer, in combination with gemcitabine.
Testing the Safety of an Immunotherapy Combination After Surgery
A new clinical trial tests the safety of a monoclonal antibody and personalized cancer vaccine combined with chemotherapy after surgery to remove pancreatic cancer.
Drug Combination to Combat Pancreatic and other Gastrointestinal Cancers
Researchers are combining TAS-102, an approved drug for colorectal cancer, and nanoliposomal irinotecan, to see if they work on pancreatic and other gastrointestinal cancers.
CAR T Cell Trial Targets Mesothelin
In an immunotherapy clinical trial, Dr. Mark O'Hara is using CAR T cells to attack mesothelin-expressing tumor cells in pancreatic cancer.
Immunotherapy to Attack a Common Pancreatic Cancer Mutation
Researchers are testing a type of immunotherapy to attack a variant of the KRAS mutation; KRAS mutations occur in almost all pancreatic cancers.
Combination Delivers a Dual Punch to Pancreatic Cell Growth
Dr. Conan Kinsey outlines a clinical trial that has moved quickly from the lab to phase I, with a dual approach to delivering pancreatic cancer treatment.
Targeting Cancer-Associated Wasting With Experimental Immunotherapy
Wasting, or cachexia, is the focus of a clinical trial testing a cachexia immunotherapy treatment combined with standard pancreatic cancer treatment.